Umedica Laboratories Private Limited Roxithromycin Export Data — India (DGFT 2022–2026)

Name: Umedica Laboratories Private Limited Roxithromycin Export Records India — #7 Exporter, 3 Shipments, $93.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Roxithromycin

India Pharmaceutical Trade Intelligence

$4.2M78 Suppliers30 CountriesHS 30049099

ExportsIndia → VIETNAM33.9%India → CAMBODIA18.3%

ImportsGERMANY → India$752

#1 Supplier: BRAWN LABORATORIES

Umedica Laboratories Private Limited — Roxithromycin Exporter #7 | $93.2K Trade Value | TransData Nexus | TransData Nexus

Umedica Laboratories Private Limited — Roxithromycin Exporter Profile

Indian Pharmaceutical Exporter · #7 for Roxithromycin · $93.2K export value · DGFT Verified

Umedica Laboratories Private Limited is the #7 Indian exporter of Roxithromycin with $93.2K in export value and 3 verified shipments. Umedica Laboratories Private Limited holds a 2.2% market share in Roxithromycin exports across 1 countries. The company exports 11 pharmaceutical products worth $32.2M across 8 therapeutic categories.

Umedica Laboratories Private Limited — Roxithromycin Export Profile: Buyers & Destinations

Umedica Laboratories Private Limited Roxithromycin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Roxithromycin?

Country	Value	Shipments	Share
VIETNAM	$900.0K	18	24.8%
CAMBODIA	$763.2K	68	21.0%
AUSTRALIA	$758.8K	54	20.9%
NEW ZEALAND	$405.4K	10

Who Are the Top Buyers of Roxithromycin from India?

Buyer	Country	Value	Orders
TEVA PHARMA (NEW ZEALAND) LIMITED	NEW ZEALAND	$235.2K	5
MILITARY COMMERICAL JOINT STOCK BANK	VIETNAM	$200.0K	4
APOTEX PTY LTD.,	AUSTRALIA	$182.5K	11
TEVA PHARMA NEW ZEALAND LIMITED	NEW ZEALAND	$170.2K	5
ISKP PHARMA CO., LTD	CAMBODIA	$164.8K	4
HEUMANN PHARMA GMBH CO. GENERICA KG	GERMANY	$159.7K	10
ARROW PHARMACEUTICALS PTY LTD,	AUSTRALIA	$150.2K	10
OPHAM - ROUTE DIGUE ANDRANOAMBO	MADAGASCAR	$129.0K	8
ARROW PHARMACEUTICALS PTY LTD.,	AUSTRALIA	$112.2K	7
CAMEL INTERNATIONAL IM-EXPORT	VIETNAM	$93.2K	3

India's Roxithromycin is purchased by 125 buyers worldwide. The top buyer is TEVA PHARMA (NEW ZEALAND) LIMITED (NEW ZEALAND), followed by MILITARY COMMERICAL JOINT STOCK BANK and APOTEX PTY LTD.,.

How Does Umedica Laboratories Private Limited Compare to Nearest Roxithromycin Exporters?

Exporters ranked immediately above and below #7 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
5	GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED	$135.0K	12	3	$11.3K
6	MICRO LABS LIMITED	$129.4K	7	2	$18.5K
7	UMEDICA LABORATORIES PRIVATE LIMITED ★	$93.2K	3	1	$31.1K
8	MERCURY LABORATORIES LIMITED	$73.2K	5	3	$14.6K
9	CADILA HEALTHCARE LIMITED	$51.2K	13	1	$3.9K

Umedica Laboratories Private Limited ranks #7 among 78 Indian Roxithromycin exporters. Average shipment value of $31.1K compared to the market average of $36.7K. The closest competitors by value are GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED and MICRO LABS LIMITED.

Which Indian Ports Ship Roxithromycin Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	64	15.0%
SAHAR AIR CARGO ACC (INBOM4)	40	9.4%
SAHAR AIR	35	8.2%
Bombay Air	29	6.8%
NHAVA SHEVA SEA (INNSA1)	25	5.9%
DELHI AIR	24	5.6%
TUGLAKABAD ICD	14	3.3%
BANGALORE ICD	14	3.3%

Geopolitical & Trade Policy Impact on Umedica Laboratories Private Limited's Roxithromycin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Umedica Laboratories. The Israel-Iran conflict has led to disruptions in Middle East trade routes, particularly affecting the Red Sea shipping lanes. Major shipping lines have imposed 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, effectively increasing the cost of exporting goods through these routes. This escalation in shipping costs can erode profit margins and necessitate strategic adjustments in logistics and pricing strategies. (sgeexport.com)

Conversely, the US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian goods by the US, including a 25% tariff announced in 2025, poses a significant challenge. This tariff could lead to increased costs for Indian pharmaceutical products in the US market, potentially affecting demand and profitability. (en.wikipedia.org)

The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a promising avenue for Umedica. The FTA eliminates tariffs on Indian pharmaceutical exports to the EU, providing a competitive advantage and facilitating market expansion. This agreement is expected to open a market worth $572.3 billion for Indian pharmaceutical and MedTech exports to Europe from 2027 onward. (mordorintelligence.com)

Umedica Laboratories Private Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent Good Manufacturing Practice (GMP) requirements. Historically, non-compliance has led to import bans and reputational damage for Indian firms. For instance, in 2013, the FDA banned imports from certain Indian pharmaceutical companies due to GMP violations, highlighting the critical importance of adherence to quality standards. (comcec.org)

While specific regulatory events concerning Umedica Laboratories are not detailed in the available data, the company's sustained export performance suggests a commitment to maintaining high-quality standards and compliance with international regulations. Continuous investment in quality control systems and regulatory compliance is essential to navigate the evolving landscape and to capitalize on global market opportunities.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Roxithromycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Umedica Laboratories Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 30+ countries, 125+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Roxithromycin

Roxithromycin

Umedica Laboratories Private Limited — Roxithromycin Exporter Profile

Umedica Laboratories Private Limited — Roxithromycin Export Profile: Buyers & Destinations

Where Does India Export Roxithromycin?

Who Are the Top Buyers of Roxithromycin from India?

What Is India's Total Roxithromycin Export Value and How Much Does Umedica Laboratories Private Limited Contribute?

What Is the Average Shipment Value for Umedica Laboratories Private Limited's Roxithromycin Exports?

How Does Umedica Laboratories Private Limited Compare to Other Indian Roxithromycin Exporters?

Regulatory Requirements: Exporting Roxithromycin to Key Markets

Australia — TGA

How Does Umedica Laboratories Private Limited Compare to Nearest Roxithromycin Exporters?

Which Indian Ports Ship Roxithromycin Exports?

Geopolitical & Trade Policy Impact on Umedica Laboratories Private Limited's Roxithromycin Exports

Umedica Laboratories Private Limited — Regulatory Compliance & Quality Standards

About Umedica Laboratories Private Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Roxithromycin Export Data from Umedica Laboratories Private Limited

Roxithromycin Stats

Company Overview

Top Products by Umedica Laboratories Private Limited

Related Analysis

Need Detailed Export Data?

Data Source